NIH review cites scientists for breaking ethics rules on drug ties

A review by the NIH has concluded that 44 government scientists have violated ethics rules with their ties to pharmaceutical companies, and nine of them may have broken the law. The 44 scientists had either failed to disclose payments from drug companies, failed to get the NIH's permission to consult with them or did work for the drug companies on government time. Congressman Joe Barton said the ethical problems were "more systemic and severe than previously known."

- read this story from The New York Times for more

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.